Mon, Dec 22, 2014, 3:56 AM EST - U.S. Markets open in 5 hrs 34 mins

Recent

% | $
Quotes you view appear here for quick access.

InVivo Therapeutics Holdings Corp. Message Board

  • formerblueguy formerblueguy Nov 14, 2012 6:58 PM Flag

    Lazard Presentation

    Link to Lazard conf presentation in the release from a couple of days ago... Listened to it... poor audio... no slides available... heard something about another product to be announced in a month or so. Still early 2013 for scaffold trial start. Mfg facilty making batches of scaffold for FDA. Made mention of the steriod mfg meningitis scare-- probably implying FDA wants to make sure nothing like that happens with invivo's products. Will PARTNER in development of the hydrogel product. Paper to be submitted to journal -- scaffold was the reason for those monkeys walking again. Brought research in-house from outsourcing... hired 30 phd's = same cost of last years research expense.

    In addition, heard that they had to make "tough strategic decisions" in last couple of months. Guessing stem cell direction de-emphasized? Said upcoming year should be big one for the company... Keeps saying announcement coming soon...We shall see...

    If anybody else caught anything else of significance or if you have corrections.. please post...

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • everything you mentioned makes perfect sense-
      --the gentleman from Geron (who was on the board of directors) was replaced/left--likely because the use of neural stem cells would not be happening anytime soon due to the restrictions that have placed on their use and the lenghty time it would take to get this to get to market even if the results were good. I also agree that the recent meningitis-steroid debacle has caused to FDA to be extra vigilent about approving any "foreign body" (i.e scaffold) that could potentially be a source of infection. I am confident with all the remarkable people in Vivo has assembled (many if not most who have extensive experience with the workings of the FDA---including Robert Langer-whose track record with getting FDA patent/product approval is outstanding) everything will come together in 2013.

      Sentiment: Strong Buy

 
NVIV
1.42+0.16(+12.70%)Dec 19 3:59 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.